Id: acc4894
Group: 2sens
Protein: FRS2
Gene Symbol: FRS2
Protein Id: Q8WU20
Protein Name: FRS2_HUMAN
PTM: phosphorylation
Site: Ser
Site Sequence:
Disease Category: Nervous system diseases
Disease: Neuronal Differentiation
Disease Subtype: EGFinduced
Disease Cellline: PC-12
Disease Info:
Drug: POV
Drug Info: "The information is insufficient to accurately describe the drug ""POV"" in a formal and academic way. "
Effect: modulate
Effect Info: "The phosphatase pan - inhibitor POV can simultaneously induce the phosphorylation of threonine and tyrosine in FRS2, indicating that it may enhance various phosphorylation modifications by inhibiting phosphatase activity."
Note: no disease
Score: 2.0
Pubmed(PMID): 19652666
Sentence Index:
Sentence:

Sequence & Structure:

MGSCCSCPDKDTVPDNHRNKFKVINVDDDGNELGSGIMELTDTELILYTRKRDSVKWHYLCLRRYGYDSNLFSFESGRRCQTGQGIFAFKCARAEELFNMLQEIMQNNSINVVEEPVVERNNHQTELEVPRTPRTPTTPGFAAQNLPNGYPRYPSFGDASSHPSSRHPSVGSARLPSVGEESTHPLLVAEEQVHTYVNTTGVQEERKNRTSVHVPLEARVSNAESSTPKEEPSSIEDRDPQILLEPEGVKFVLGPTPVQKQLMEKEKLEQLGRDQVSGSGANNTEWDTGYDSDERRDAPSVNKLVYENINGLSIPSASGVRRGRLTSTSTSDTQNINNSAQRRTALLNYENLPSLPPVWEARKLSRDEDDNLGPKTPSLNGYHNNLDPMHNYVNTENVTVPASAHKIEYSRRRDCTPTVFNFDIRRPSLEHRQLNYIQVDLEGGSDSDNPQTPKTPTTPLPQTPTRRTELYAVIDIERTAAMSNLQKALPRDDGTSRKTRHNSTDLPM

Select PDB:

Known Drugs:

source: Multi-Sources

(see table)

No data.

Protein Tractability:

source: Open Targets
Small molecule
Antibody
PROTAC
Other modalities
Approved Drug
Advanced Clinical
Phase 1 Clinical
Structure with Ligand
High-Quality Ligand
High-Quality Pocket
Med-Quality Pocket
Druggable Family
Approved Drug
Advanced Clinical
Phase 1 Clinical
UniProt loc high conf
GO CC high conf
UniProt loc med conf
UniProt SigP or TMHMM
GO CC med conf
Human Protein Atlas loc
Approved Drug
Advanced Clinical
Phase 1 Clinical
Literature
UniProt Ubiquitination
Database Ubiquitination
Half-life Data
Small Molecule Binder
Approved Drug
Advanced Clinical
Phase 1 Clinical

PTM Intensity:

source: CPTAC

No data.

PTM-Disease Association:

source: PTMD

No data.

PTM-Drug Perturbation Response:

source: DecryptM
Protein Gene PTM Position Modified sequence Cell Drug pEC50 Regulation Experiment
Q8WU20 FRS2 P Ser221;Thr227 VS(ph)NAESST(ph)PKEEPSSIEDRDPQILLEPEGVK A549 Dactolisib 6.3961 up
Q8WU20 FRS2 P Ser221 VS(ph)NAESSTPK A431 Gefitinib 6.955 up
Q8WU20 FRS2 P Ser221 VS(ph)NAESSTPK A431 Gefitinib 6.7922 up
Q8WU20 FRS2 P Ser221 VS(ph)NAESSTPK A431 Afatinib 7.792 up
Q8WU20 FRS2 P Ser365 KLS(ph)RDEDDNLGPK A549 PD325901 9.2043 down
Q8WU20 FRS2 P Ser503 HNS(ph)TDLPM A431 Afatinib 7.9428 down
Q8WU20 FRS2 P Ser221;Ser225 VS(ph)NAES(ph)STPKEEPSSIEDRDPQILLEPEGVK A431 Afatinib 8.3441 down
Q8WU20 FRS2 P Ser221 VS(ph)NAESSTPKEEPSSIEDRDPQILLEPEGVK A549 PD325901 9.5394 down
Q8WU20 FRS2 P Ser226 VSNAESS(ph)TPKEEPSSIEDRDPQILLEPEGVK A549 Refametinib 7.2756 down
Q8WU20 FRS2 P Ser327 LTS(ph)TSTSDTQNINNSAQR A549 Nintedanib 5.2354 -
Q8WU20 FRS2 P Ser428 RPS(ph)LEHR A549 Nintedanib 6.7455 -
Q8WU20 FRS2 P Ser365 KLS(ph)RDEDDNLGPK A549 Nintedanib 10.3883 -
Q8WU20 FRS2 P Ser327 LTS(ph)TSTSDTQNINNSAQR A549 MK2206 6.2276 -
Q8WU20 FRS2 P Ser292 DQVSGSGANNTEWDTGYDS(ph)DERRDAPSVNK A549 MK2206 8.6754 -
Q8WU20 FRS2 P Ser503 HNS(ph)TDLPM A549 MK2206 8.7545 -
Q8WU20 FRS2 P Ser428 RPS(ph)LEHR A549 PD325901 8.9881 -
Q8WU20 FRS2 P Ser365 KLS(ph)RDEDDNLGPK A549 MK2206 11.119 -
Q8WU20 FRS2 P Ser226 VSNAESS(ph)TPKEEPSSIEDRDPQILLEPEGVK A549 Nintedanib 2 -
Q8WU20 FRS2 P Ser211 TS(ph)VHVPLEAR A549 Dasatinib 5.3626 -
Q8WU20 FRS2 P Ser365 KLS(ph)RDEDDNLGPK A549 Dasatinib 5.5719 -
Q8WU20 FRS2 P Ser327 LTS(ph)TSTSDTQNINNSAQR A549 Dasatinib 7.3312 -
Q8WU20 FRS2 P Ser428 RPS(ph)LEHR A549 Dasatinib 8.7534 -
Q8WU20 FRS2 P Ser428 RPS(ph)LEHR A549 Dasatinib 8.8094 -
Q8WU20 FRS2 P Ser221;Ser225 VS(ph)NAES(ph)STPKEEPSSIEDRDPQILLEPEGVK A549 Dasatinib 8.8711 -
Q8WU20 FRS2 P Ser503 HNS(ph)TDLPM A549 Dasatinib 10.6093 -
Q8WU20 FRS2 P Ser292 DQVSGSGANNTEWDTGYDS(ph)DERR A549 Dasatinib 10.8636 -
Q8WU20 FRS2 P Ser327 LTS(ph)TSTSDTQNINNSAQR A549 Dactolisib 2 -
Q8WU20 FRS2 P Ser428 RPS(ph)LEHR A549 Dactolisib 5.4867 -
Q8WU20 FRS2 P Ser365 KLS(ph)RDEDDNLGPK A549 Dactolisib 6.3565 -
Q8WU20 FRS2 P Ser226 VSNAESS(ph)TPKEEPSSIEDRDPQILLEPEGVK A549 Dactolisib 6.3836 -
Q8WU20 FRS2 P Ser226;Thr227 VSNAESS(ph)T(ph)PKEEPSSIEDRDPQILLEPEGVK A549 Refametinib 7.8874 -
Q8WU20 FRS2 P Ser428 RPS(ph)LEHR KYSE-520 SHP099 14 -
Q8WU20 FRS2 P Ser221;Ser225 VS(ph)NAES(ph)STPKEEPSSIEDRDPQILLEPEGVK A549 Tideglusib 8.2774 -
Q8WU20 FRS2 P Ser365 KLS(ph)RDEDDNLGPK A549 Tideglusib 8.7675 -
Q8WU20 FRS2 P Ser428 RPS(ph)LEHR A549 Tideglusib 10.3211 -
Q8WU20 FRS2 P Ser327 LTS(ph)TSTSDTQNINNSAQR A549 Tideglusib 11.0676 -
Q8WU20 FRS2 P Ser226 VSNAESS(ph)TPKEEPSSIEDRDPQILLEPEGVK A549 Staursporin 5.257 -
Q8WU20 FRS2 P Ser503 HNS(ph)TDLPM A549 Staursporin 5.5142 -
Q8WU20 FRS2 P Ser292 DQVSGSGANNTEWDTGYDS(ph)DERR A549 Refametinib 2 -
Q8WU20 FRS2 P Ser211 TS(ph)VHVPLEAR A549 Refametinib 5.7657 -
Q8WU20 FRS2 P Ser428 RPS(ph)LEHR A549 Refametinib 7.6083 -
Q8WU20 FRS2 P Ser327 LTS(ph)TSTSDTQNINNSAQR A549 Refametinib 7.7526 -
Q8WU20 FRS2 P Ser221;Thr227 VS(ph)NAESST(ph)PKEEPSSIEDRDPQILLEPEGVK A549 PD325901 10.6601 -
Q8WU20 FRS2 P Ser225 VSNAES(ph)STPKEEPSSIEDRDPQILLEPEGVK A549 Pictilisib 6.7724 -
Q8WU20 FRS2 P Ser365 KLS(ph)RDEDDNLGPK A549 Pictilisib 7.2667 -
Q8WU20 FRS2 P Ser428 RPS(ph)LEHR A549 Pictilisib 8.053 -
Q8WU20 FRS2 P Ser226 VSNAESS(ph)TPKEEPSSIEDRDPQILLEPEGVK A549 Pictilisib 8.1476 -
Q8WU20 FRS2 P Ser327 LTS(ph)TSTSDTQNINNSAQR A549 Pictilisib 8.6314 -
Q8WU20 FRS2 P Ser211 TS(ph)VHVPLEAR A549 Pictilisib 10.8936 -
Q8WU20 FRS2 P Ser292 DQVSGSGANNTEWDTGYDS(ph)DERR A549 PD325901 8.2357 -
Q8WU20 FRS2 P Ser211 TS(ph)VHVPLEAR A549 PD325901 8.2431 -
Q8WU20 FRS2 P Ser503 HNS(ph)TDLPM A549 PD325901 8.4753 -
Q8WU20 FRS2 P Ser365 KLS(ph)RDEDDNLGPK A549 AZD8055 8.8278 -
Q8WU20 FRS2 P Ser221;Ser225 VS(ph)NAES(ph)STPKEEPSSIEDRDPQILLEPEGVK A431 Afatinib 8.0823 -
Q8WU20 FRS2 P Ser292 DQVSGSGANNTEWDTGYDS(ph)DERR A431 Dasatinib 6.5871 -
Q8WU20 FRS2 P Ser169 HPS(ph)VGSAR A431 Dasatinib 7.2561 -
Q8WU20 FRS2 P Ser428 RPS(ph)LEHR A431 Dasatinib 7.2607 -
Q8WU20 FRS2 P Ser221 VS(ph)NAESSTPK A431 Dasatinib 5.4432 -
Q8WU20 FRS2 P Ser169 HPS(ph)VGSAR A431 Dasatinib 8.3876 -
Q8WU20 FRS2 P Ser428 RPS(ph)LEHR A431 Dasatinib 9.8809 -
Q8WU20 FRS2 P Ser221;Ser226 VS(ph)NAESS(ph)TPKEEPSSIEDRDPQILLEPEGVK A431 Dasatinib 5.4905 -
Q8WU20 FRS2 P Ser503 HNS(ph)TDLPM A431 Dasatinib 5.8489 -
Q8WU20 FRS2 P Ser428 RPS(ph)LEHR A431 Dasatinib 8.284 -
Q8WU20 FRS2 P Ser428 RPS(ph)LEHR A431 Afatinib 7.7643 -
Q8WU20 FRS2 P Ser221 VS(ph)NAESSTPK A431 Afatinib 7.8424 -
Q8WU20 FRS2 P Ser503 HNS(ph)TDLPM A431 Dasatinib 5.4921 -
Q8WU20 FRS2 P Ser292 DQVSGSGANNTEWDTGYDS(ph)DERR A431 Afatinib 8.5087 -
Q8WU20 FRS2 P Ser169 HPS(ph)VGSAR A431 Afatinib 9.8708 -
Q8WU20 FRS2 P Ser503 HNS(ph)TDLPM A431 Afatinib 7.1901 -
Q8WU20 FRS2 P Ser428 RPS(ph)LEHR A431 Afatinib 7.2598 -
Q8WU20 FRS2 P Ser292 DQVSGSGANNTEWDTGYDS(ph)DERR A431 Afatinib 7.6483 -
Q8WU20 FRS2 P Ser169 HPS(ph)VGSAR A431 Afatinib 10.0534 -
Q8WU20 FRS2 P Ser428 RPS(ph)LEHR A431 Afatinib 8.0821 -
Q8WU20 FRS2 P Ser428 RPS(ph)LEHR A431 Afatinib 4.1718 -
Q8WU20 FRS2 P Ser169 HPS(ph)VGSAR A431 Afatinib 5.6799 -
Q8WU20 FRS2 P Ser365 KLS(ph)RDEDDNLGPK A431 Afatinib 6.5539 -
Q8WU20 FRS2 P Ser428 RPS(ph)LEHR A431 Gefitinib 6.0736 -
Q8WU20 FRS2 P Ser428 RPS(ph)LEHR A549 AZD8055 6.9917 -
Q8WU20 FRS2 P Ser221 VS(ph)NAESSTPK A431 Afatinib 8.2018 -
Q8WU20 FRS2 P Ser327 LTS(ph)TSTSDTQNINNSAQR A549 AZD8055 10.9914 -
Q8WU20 FRS2 P Ser503 HNS(ph)TDLPM A431 Gefitinib 5.6 -
Q8WU20 FRS2 P Ser428 RPS(ph)LEHR A431 Gefitinib 6.1341 -
Q8WU20 FRS2 P Ser292 DQVSGSGANNTEWDTGYDS(ph)DERR A431 Gefitinib 8.2774 -
Q8WU20 FRS2 P Ser292 DQVSGSGANNTEWDTGYDS(ph)DERR A431 Gefitinib 6.2948 -
Q8WU20 FRS2 P Ser169 HPS(ph)VGSAR A431 Gefitinib 7.7493 -
Q8WU20 FRS2 P Ser428 RPS(ph)LEHR A431 Gefitinib 8.4217 -
Q8WU20 FRS2 P Ser428 RPS(ph)LEHR A431 Gefitinib 6.6068 -
Q8WU20 FRS2 P Ser292 DQVSGSGANNTEWDTGYDS(ph)DERR A431 Gefitinib 7.6086 -
Q8WU20 FRS2 P Ser211 TS(ph)VHVPLEAR A549 Dactolisib 7.4412 -
Q8WU20 FRS2 P Ser292 DQVSGSGANNTEWDTGYDS(ph)DERR A431 Gefitinib 7.2793 -
Q8WU20 FRS2 P Ser169 HPS(ph)VGSAR A431 Gefitinib 8.3797 -
Q8WU20 FRS2 P Ser503 HNS(ph)TDLPM A431 Dasatinib 5.441 -
Q8WU20 FRS2 P Ser428 RPS(ph)LEHR A431 Dasatinib 6.1384 -
Q8WU20 FRS2 P Ser169 HPS(ph)VGSAR A431 Dasatinib 7.5336 -
Q8WU20 FRS2 P Ser292 DQVSGSGANNTEWDTGYDS(ph)DERR A431 Dasatinib 8.632 -
Q8WU20 FRS2 P Ser365 KLS(ph)RDEDDNLGPK A431 Dasatinib 9.2361 -
Q8WU20 FRS2 P Ser226;Thr227;Ser233 VSNAESS(ph)T(ph)PKEEPS(ph)SIEDRDPQILLEPEGVK A431 Dasatinib 16.5229 -
Q8WU20 FRS2 P Ser221;Ser225;Ser233 VS(ph)NAES(ph)STPKEEPS(ph)SIEDRDPQILLEPEGVK A431 Dasatinib 3.9843 -
Q8WU20 FRS2 P Ser221;Ser225 VS(ph)NAES(ph)STPKEEPSSIEDRDPQILLEPEGVK A431 Dasatinib 5.4697 -

pEC50 Note: pEC50 is the negative logarithm of EC50 (half-maximal effective concentration, dosage unit Mol), calculated as pEC50 = -log10(EC50), which quantifies the potency of a drug or compound.

Function score:

source: funscoR

No data.

Cross Links: